- 10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing
- 10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Noncompliance
- 10X Capital Venture Acquisition Corp. III Announces Expected Change in Management
- 10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
- 10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American
- Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.07 |
---|---|
High | 11.07 |
Low | 11.05 |
Bid | 11.05 |
Offer | 11.06 |
Previous close | 11.03 |
Average volume | 8.26k |
---|---|
Shares outstanding | 13.19m |
Free float | 13.19m |
P/E (TTM) | -- |
Market cap | 145.53m USD |
EPS (TTM) | -0.0842 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:05 BST.
More ▼